Navigation Links
AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
Date:11/22/2011

IRVINE, Calif., Nov. 22, 2011 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced the recent presentation by Diana Shih, Ph.D., Associate Professor of Medicine, Division of Cardiology at the David Geffen School of Medicine at UCLA, at the 2011 American Heart Association (AHA) Scientific Sessions in Orlando, Florida.  Dr. Shih's presentation included information on research sponsored by the Company which demonstrated that dietary supplementation of AHRO-001 resulted in a 95% reduction in arterial plaque formation at the innominate artery when compared to the control group.

The study results also revealed significant reduction in plasma cholesterol and dietary cholesterol absorption in the test subjects that received HDCA. HDCA supplementation also improved HDL function as measured by cholesterol efflux assay. These factors indicate multiple methods of action for an anti-atherogenic effect, suggesting a clear potential for new anti-atherosclerotic therapy.

"We are extremely pleased with the results of the UCLA study and want to thank Dr. Shih for all of her efforts on this presentation," said Thomas W. Gardner, CEO of AtheroNova. "The data from this study confirms and enhances our initial research and understanding of the compounds. As a result, we are moving forward with the preparation of an Investigative New Drug (IND) application with the Food and Drug Administration (FDA) for our atherosclerotic plaque regression compounds, in addition to, preparations for entry into Phase I human trials during 2012."

"Presenting such positive data to an audience of industry peers at AHA validates the potential of AtheroNova's compounds," Gardner concluded. 

Dr. Shih's presentation can be viewed on the American Heart Association's website at www.scientificsessions.org'/>"/>

SOURCE AtheroNova Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AtheroNova Rodman & Renshaw Presentation Now Online at www.AtheroNova.com
2. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
3. Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight
4. SRI International Awarded Two National Cancer Institute Preclinical Development Service Contracts
5. Dr. Ken Kaitin, Tufts CSDD, Keynotes Preclinical Conference
6. Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
7. Merrimack Announces Presentation of Preclinical Data at the 14th World Conference on Lung Cancer
8. Micell Technologies Reports Preclinical Data for MiStent™ Drug-Eluting Coronary Stent to be Presented at EuroPCR
9. Tolerx Presents Preclinical Data on Novel Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses
10. Otonomys OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies
11. QPS Expands Into Toxicology Services With Acquisition of the Preclinical Unit of DCB Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 The prestigious "Discovery or Exploration ... recently awarded to Juliana Hillis and Kaylie O’Connell, students ... project, “From an Egg, Everything: America’s First IVF Baby". ... for the National History Day program during a week-long ... educators in Washington, D.C. , The growing popularity of ...
(Date:7/29/2014)... EXpressLO LLC, expert provider of focused ... solutions, has been granted patent number 8,789,826 by the ... incorporating a unique specimen carrier support grid design described ... company patent for EXpressLO LLC awarded to founder and ... complementary patents extend EXpressLO’s portfolio of intellectual property. The ...
(Date:7/28/2014)... DIEGO , July 28, 2014 ... cultivation technologies, today announced the appointment of biotechnology veteran ... of the board of directors. Levine replaces Cynthia ,CJ, ... immediately. She will remain chairman of the company,s board ... on Sapphire Energy,s mission to deliver commercial scale algae-based ...
(Date:7/28/2014)... According to a new market research ... (Bone and Joint) Market (By Technology - Stem ... - Bone Graft Substitutes, Osteoarticular Diseases, Allogeneic Products, ... Size, Share, Growth, Trends and Forecast, 2013 - ... market was valued at USD 2.6 billion in ...
Breaking Biology Technology:In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3EXpressLO LLC Granted Second U.S. Patent for Innovative Specimen Preparation Methods 2Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4
... Chicago-based Celsis International, a leading global life sciences company, ... process and will de-list from the London Stock Exchange ... "Celsis has a very strong track record of consistent ... results were not being reflected in our share price," ...
... N.J., Oct. 9 Soligenix, Inc. (Soligenix or the ... announced today that Robert J. Rubin, MD, has been ... has had a distinguished career in the healthcare industry ... as president of the national health policy and management ...
... WA, and VANCOUVER, Oct. 9 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... Cormack, president and chief executive officer of OncoGenex, has ... The Year(R). The Ernst & Young Entrepreneur Of The ... entrepreneurs that are building successful, dynamic businesses. , "I ...
Cached Biology Technology:Chicago-Based Celsis International Goes Private 2Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors 2Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors 3Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors 4OncoGenex Pharmaceuticals CEO Named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R) in the Health Sciences Category 2OncoGenex Pharmaceuticals CEO Named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R) in the Health Sciences Category 3
(Date:7/28/2014)... John Essigmann and colleagues from the University of Washington had ... they could induce the virus to mutate uncontrollably, they could ... strategy that our immune system uses against many viruses. ... to mutate at an enhanced rate, as expected. But it ... clinical trial reported in 2011. In a new study, however, ...
(Date:7/28/2014)... Eight of the top 10 U.S. cities that have ... public inconveniences as frequent road closures, overwhelmed storm drains ... a new NOAA technical report. , This nuisance flooding, ... three U.S. coasts, between 300 and 925 percent since ... Nuisance Flood Frequency Changes around the United States, also ...
(Date:7/28/2014)... himself the bug hunter, but the target of his ... and identified with special methods and instruments. Benjamin Hause, ... Diagnostic Laboratory at Kansas State University, recently published an ... which is an important find in the United States. ... didn,t know what it was," Hause said. "We used ...
Breaking Biology News(10 mins):Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3
... Researchers at the University of Cambridge have discovered a ... within the body, a breakthrough that could lead to ... , Dr. Pietro Mastroeni, Professor Duncan Maskell at ... pioneered the integration of mathematical models with observational data ...
... had narrow, pointed teeth, which were more suited to tearing ... then grind their food? Until recently many researchers have assumed ... their muscular stomach these then acted as a kind of ... correct, as scientists at the universities of Bonn and Tübingen ...
... regulate neuronal signaling in the brain and spinal cord ... mouse with a mutation affecting a neuronal zinc target, ... modulating signaling among the neurons. Significantly, they found the ... as children with the genetic disorder called "startle disease," ...
Cached Biology News:Researchers map spread of pathogens in the human body 2Dinosaurs -- stones did not help with digestion 2Dinosaurs -- stones did not help with digestion 3Zinc plays important role in brain circuitry 2
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Request Info...
Biology Products: